Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

KRAS mutant inhibitor KQB365

An inhibitor of one or more KRAS mutations, with potential antineoplastic activity. Upon administration, KRAS mutant inhibitor KQB365 targets, binds to and inhibits one or more KRAS mutations, thereby inhibiting KRAS mutant-dependent signaling. This inhibits the proliferation of and induces apoptosis in tumor cells in which KRAS is mutated. KRAS plays an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	KRAS inhibitor KQB365
Code name:	KQB 365 KQB-365 KQB365

KRAS mutant inhibitor KQB365

Search NCI's Drug Dictionary